Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1950 | Inhaled sedation Wiki | 1.00 |
| drug253 | Allocetra-OTS Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The authors hypothesized that inhaled sedation, either with isoflurane or sevoflurane, might be associated with improved clinical outcomes in patients with COVID-19-related ARDS, compared to intravenous sedation. The authors therefore designed the "Inhaled Sedation for COVID-19-related ARDS" (ISCA) non-interventional, observational, multicenter study of data collected from the patients' medical records in order to: 1. assess the efficacy of inhaled sedation in improving a composite outcome of mortality and time off the ventilator at 28 days in patients with COVID-19-related ARDS, in comparison to a control group receiving intravenous sedation (primary objective), 2. investigate the effects of inhaled sedation, compared to intravenous sedation, on lung function as assessed by gas exchange and physiologic measures in patients with COVID-19-related ARDS (secondary objective), 3. report sedation practice patterns in critically ill patients during the COVID-19 pandemics (secondary objective).
Description: Ventilator-free days to day 28 are defined as the number of days from the time of initiating unassisted breathing to day 28 after intubation, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to day 28. If a patient returns to assisted breathing and subsequently achieves unassisted breathing to day 28, VFDs will be counted from the end of the last period of assisted breathing to day 28. A period of assisted breathing lasting less than 24 hours and for the purpose of a surgical procedure will not count against the VFD calculation. If a patient was receiving assisted breathing at day 27 or died prior to day 28, VFDs will be zero. Patients transferred to another hospital or other health care facility will be followed to day 28 to assess this endpoint.
Measure: Number of days off the ventilator (VFD28, for ventilator-free days), taking into account death as a competing event Time: Day 28 after inclusionDescription: All-cause mortality
Measure: All-cause mortality Time: Days 7, 14, and 28 after inclusionDescription: Ventilator-free days to days 7 and 14 are defined as the number of days from the time of initiating unassisted breathing to day 7 and 14 after intubation, assuming survival for at least two consecutive calendar days after initiating unassisted breathing and continued unassisted breathing to days 7 and 14 If a patient returns to assisted breathing and subsequently achieves unassisted breathing to days 7 and 14 , VFDs will be counted from the end of the last period of assisted breathing to days 7 and 14. A period of assisted breathing lasting less than 24 hours and for the purpose of a surgical procedure will not count against the VFD calculation. If a patient was receiving assisted breathing at day 6 or 13 or died prior to days 7 and 14, respectively,VFDs to days 7 and 14 will be zero. Patients transferred to another hospital or other health care facility will be followed to days 7 and 14 to assess this endpoint.
Measure: Ventilator-free days Time: Days 7 and 14 after inclusionDescription: Number of days alive and not in the ICU from inclusion to day 28
Measure: ICU-free days Time: Day 28 after inclusionDescription: Total duration of controlled mechanical ventilation to day 28
Measure: Duration of invasive mechanical ventilation Time: Day 28 after inclusionDescription: Total duration of controlled mechanical ventilation to day 28
Measure: Duration of controlled mechanical ventilation Time: Day 28 after inclusionDescription: Arterial hypoxemia, as assessed by the partial pressure of arterial oxygen-to-fraction of inspired oxygen ratio (PaO2/FiO2)
Measure: Physiological measures of lung function Time: Days 1, 2, 3, 4, 5, 6, and 7 from inclusionDescription: Partial pressure of arterial carbon dioxide (PaCO2)
Measure: Physiological measures of lung function Time: Days 1, 2, 3, 4, 5, 6, and 7 from inclusionDescription: Inspiratory plateau pressure
Measure: Physiological measures of lung function Time: Days 1, 2, 3, 4, 5, 6, and 7 from inclusionDescription: Driving pressure
Measure: Physiological measures of lung function Time: Days 1, 2, 3, 4, 5, 6, and 7 from inclusionDescription: Mode of mechanical ventilation (assisted versus controlled)
Measure: Physiological measures of lung function Time: Days 1, 2, 3, 4, 5, 6, and 7 from inclusionDescription: If available, 100 ms occlusion pressure (P0.1), a marker of respiratory drive
Measure: Physiological measures of lung function Time: Days 1, 2, 3, 4, 5, 6, and 7 from inclusionDescription: Development of pneumothorax
Measure: Development of complications Time: Day 7 from inclusionDescription: Supraventricular tachycardia
Measure: Development of complications Time: Day 7 from inclusionDescription: New onset atrial fibrillation
Measure: Development of complications Time: Day 7 from inclusionDescription: Total duration (in days) of vasopressor use
Measure: Duration of vasopressor use Time: Day 28 after inclusionDescription: Total duration (in days)of renal replacement therapy
Measure: Duration of renal replacement therapy Time: Day 28 after inclusionDescription: Adjuvant therapies are defined as: prone position, recruitment maneuvers, inhaled nitric oxide, inhaled epoprostenol sodium, high frequency ventilation, ECMO, neuromuscular blockade
Measure: Duration (in days) of any adjuvant therapies Time: Day 7 from inclusionDescription: Number of days with continuous neuromuscular blockade
Measure: Duration of continuous neuromuscular blockade Time: Day 28 from inclusionDescription: Sedation drug(s) used (name(s))
Measure: Type of sedation practices Time: Day 28 from inclusionDescription: Number of days with sedation
Measure: Duration of sedation practices Time: Day 28 from inclusionDescription: If inhaled sedation, device used to deliver it
Measure: Modalities of sedation practices Time: Day 28 from inclusionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports